GOAL

The goal is to make arfolitixorin available worldwide and thereby improve the prognosis for cancer patients treated with the 5-FU-based therapies that constitute standard treatment for many cancers. As a first step, we are working to get arfolitixorin approved for the treatment of metastatic colorectal cancer – the second leading cause of cancer-related deaths worldwide. With only a 14 percent five-year survival rate, there is an urgent need to improve treatment outcomes.

Today, 5-FU is combined with a folate to increase the treatment effect. Arfolitixorin is a new form of folate that, in contrast to current drugs, does not require conversion and metabolization in the body before it becomes active, which is expected to lead to significant efficacy benefits.

Based on the evidence and knowledge about arfolitixorin generated to date, the strong collaboration established with both clinical experts and other partners, and the knowledge and experience available in the organization, Isofol is now well positioned to continue the clinical development of arfolitixorin. The goal is clear: to improve cancer treatment for millions of patients and thereby create significant value for shareholders, employees and society at large. A new and exciting phase in the company’s development has just begun.